BioStock: Cyxone is exploring new treatment possibilities for T20K

After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further validate these findings and to deepen the understanding of T20K’s mode of action. The aim of the project is to prepare for a clinical phase I study with the new administration form. BioStock reached out to COO Carl-Magnus Högerkorp and Non-Clinical Project Manager Sally Abdelmoaty for a comment.

Read the full interview at biostock.se:

https://www.biostock.se/en/cyxone-is-exploring-new-treatment-possibilities-for-t20k/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/